Abstract:Congenital heart disease (CHD) is the most common type of developmental abnormality in humans, and is a leading cause for substantially increased morbidity and mortality in affected individuals. Increasing studies demonstrates a pivotal role of genetic defects in the pathogenesis of CHD, and presently mutations in more than 60 genes have been associated with CHD. Nevertheless, CHD is of pronounced genetic heterogeneity, and the genetic basis underpinning CHD in a large proportion of patients remains unclear. In the present study, the whole coding exons and splicing donors/acceptors of the MEF2C gene, which codes for a transcription factor essential for normal cardiovascular development, were sequenced in 200 unrelated patients affected with CHD, and a novel heterozygous missense mutation, p.L38P, was identified in an index patient with patent ductus arteriosus (PDA) and ventricular septal defect (VSD). Genetic scan of the mutation carrier's family members available showed that the mutation was present in all affected family members but absent in unaffected family members. Analysis of the proband's pedigree revealed that the mutation co-segregated with PDA, which was transmitted as an autosomal dominant trait with complete penetrance. The mutation changed the amino acid that was completely conserved evolutionarily, and did not exist in 300 unrelated, ethnically-matched healthy individuals used as controls. Functional deciphers by using a dual-luciferase reporter assay system unveiled that the mutant MEF2C protein had a significantly reduced transcriptional activity. Furthermore, the mutation significantly diminished the synergistic activation between MEF2C and GATA4, another cardiac core transcription factor that has been causally linked to CHD. In conclusion, this is the first report on the association of a MEF2C loss-of-function mutation with an increased vulnerability to CHD in humans, which provides novel insight into the molecular mechanisms underlying CHD, implying potential implications for early diagnosis and timely prophylaxis of CHD.

Mutation of Mef2a in an Inherited Disorder with Features of Coronary Artery Disease

Transcription factor MEF2A mutations in patients with coronary artery disease

Mutant LRP6 Impairs Endothelial Cell Functions Associated with Familial Normolipidemic Coronary Artery Disease.

Novel 6-Bp Deletion in MEF2A Linked to Premature Coronary Artery Disease in a Large Chinese Family.

MEF2C Loss-of-function Mutation Contributes to Congenital Heart Defects.

Advances in the genetic basis of coronary artery disease

MEF2C loss-of-function mutation associated with familial dilated cardiomyopathy.

Abstract 1681: Haploinsufficiency of MEF2A Increases Risk of Atherosclerosis in Mice

A Novel MEF2C Loss-of-Function Mutation Associated with Congenital Double Outlet Right Ventricle

Detection and functional characterization of a novel <i>MEF2A</i> variation responsible for familial dilated cardiomyopathy

Variants in Exon 11 of MEF2A Gene and Coronary Artery Disease: Evidence from a Case-Control Study, Systematic Review, and Meta-Analysis.

MEF2A Gene and Susceptibility to Coronary Artery Disease in the Chinese People.

A Study of transcription factor MEF2A gene polymorphisms in patients with coronary artery disease

Molecular Genetics of Coronary Artery Disease

The Effects of Myocyte Enhancer Factor 2A Gene on the Proliferation, Migration and Phenotype of Vascular Smooth Muscle Cells.

Role of MEF2 in Cardiac Development and Cardiovascular Diseases

Myocyte enhancer factor 2A delays vascular endothelial cell senescence by activating the PI3K/p-Akt/SIRT1 pathway

Mutant NOTCH3ECD Triggers Defects in Mitochondrial Function and Mitophagy in CADASIL Cell Models

CASZ1 Loss-of-function Mutation Contributes to Familial Dilated Cardiomyopathy

Genetic Susceptibility to Myocardial Infarction and Coronary Artery Disease

De Novo Mutation Enables NOTCH3ECD Aggregation and Mitochondrial Dysfunction Via Interactions with BAX and BCL-2.